Karuna appoints former BioXcel exec as chief commercial officer

Jan. 31, 2023 6:54 AM ETKaruna Therapeutics, Inc. (KRTX), BTAIBy: Ravikash, SA News Editor

Laptop computer stand on wooden meeting table


  • Karuna Therapeutics (NASDAQ:KRTX) appointed Will Kane as chief commercial officer (CCO), effective Feb. 6.
  • Most recently, Kane served as the executive vice president and CCO at BioXcel Therapeutics (NASDAQ:BTAI). Kane has over 30 years of experience in the pharmaceutical industry and has held senior level commercial positions at Allergan, Pfizer, and Sepracor, said Karuna on Tuesday in a press release.
  • "Will is an exceptional leader and has extensive commercial operations experience, which will be invaluable as we focus our attention on the potential approval and launch of KarXT in schizophrenia," said Karuna President and CEO Bill Meury.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.